Autoimmune diseases, immune modulation, inflammation, and self-tolerance
169 articles
Real-world study reveals sarilumab and JAK inhibitors work equally well for rheumatoid arthritis, but sarilumab causes fewer infections.
JAK inhibitors outperform traditional treatments for rheumatoid arthritis but carry cardiovascular and infection risks.
Pfizer's oral JAK inhibitor demonstrated efficacy comparable to adalimumab for treating moderate to severe rheumatoid arthritis.
New research reveals how RA affects muscle biomechanics within 6 months of symptom onset, offering insights for early intervention.
Large Hong Kong registry study tracked how well patients stayed on newer JAK inhibitors versus traditional TNF blockers for RA treatment.
Scientists identify key mechanism that determines why some immune thrombocytopenia patients maintain remission after stopping treatment.
Revolutionary cancer treatment adapted for autoimmune diseases achieves drug-free remission in lupus trials, with RA applications emerging.
Researchers outline the scientific roadmap needed to cure autoimmunity without lifelong immunosuppressive drugs.
Local hormone system in joints fuels rheumatoid arthritis and osteoarthritis through distinct inflammatory pathways.
New study finds JAK inhibitors are as safe as other RA treatments for reproductive health in women of childbearing age.
New research reveals intermittent fasting forces immune memory cells from their protective niches, potentially compromising long-term immunity.
Researchers modified NK and T cells with special receptors that help them track down and infiltrate solid tumors more effectively.
